News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
432,170 Results
Type
Article (21973)
Company Profile (172)
Press Release (410025)
Section
Business (134839)
Career Advice (1034)
Deals (24526)
Drug Delivery (99)
Drug Development (53555)
Employer Resources (88)
FDA (10889)
Job Trends (10209)
News (228785)
Policy (20359)
Tag
Academia (1133)
Alliances (37321)
Alzheimer's disease (663)
Approvals (10848)
Artificial intelligence (121)
Bankruptcy (202)
Best Places to Work (7814)
Biotechnology (87)
Cancer (661)
Cardiovascular disease (73)
Career advice (852)
Cell therapy (107)
Clinical research (43813)
Collaboration (302)
Compensation (84)
COVID-19 (1345)
C-suite (74)
Data (735)
Diabetes (111)
Diagnostics (3848)
Drug pricing (92)
Earnings (48509)
Employer resources (81)
Events (62301)
Executive appointments (244)
FDA (11261)
Funding (224)
Gene therapy (101)
GLP-1 (507)
Government (2197)
Healthcare (10008)
Infectious disease (1402)
Inflammatory bowel disease (77)
Interviews (140)
IPO (9952)
Job creations (2660)
Job search strategy (760)
Layoffs (266)
Legal (4693)
Lung cancer (116)
Manufacturing (157)
Medical device (7712)
Medtech (7715)
Mergers & acquisitions (14663)
Metabolic disorders (346)
Neuroscience (841)
NextGen Class of 2024 (4002)
Non-profit (1687)
Northern California (884)
Obesity (216)
Opinion (182)
Patents (80)
People (40191)
Pharmaceutical (77)
Phase I (13568)
Phase II (18534)
Phase III (15009)
Pipeline (309)
Policy (73)
Postmarket research (1709)
Preclinical (4914)
Radiopharmaceuticals (181)
Rare diseases (158)
Real estate (3996)
Regulatory (14301)
Research institute (1196)
Resumes & cover letters (165)
Southern California (788)
Startups (2431)
United States (8398)
Vaccines (253)
Weight loss (187)
Date
Today (81)
Last 7 days (542)
Last 30 days (2425)
Last 365 days (23719)
2024 (21654)
2023 (26155)
2022 (34489)
2021 (37184)
2020 (36159)
2019 (30394)
2018 (23052)
2017 (22450)
2016 (21223)
2015 (24265)
2014 (18899)
2013 (16084)
2012 (17242)
2011 (17451)
2010 (15659)
Location
Africa (487)
Arizona (80)
Asia (29227)
Australia (3799)
California (1988)
Canada (874)
China (175)
Colorado (99)
Connecticut (90)
Europe (62421)
Florida (300)
Georgia (88)
Illinois (223)
Indiana (175)
Maryland (306)
Massachusetts (1573)
Michigan (96)
Minnesota (212)
New Jersey (681)
New York (541)
North Carolina (491)
Northern California (884)
Ohio (93)
Pennsylvania (488)
South America (763)
Southern California (788)
Texas (282)
Washington State (195)
432,170 Results for "catalent pharma solutions".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Editorial
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.
October 24, 2024
·
6 min read
·
Jef Akst
Editorial
Lilly vs. Novo: The ‘He Said, She Said’ Row About Catalent’s GLP-1 Work
With Novo Holdings’ $16.5 billion buyout of Catalent being reviewed by regulators, what work the contract drug manufacturer may or may not be performing for Eli Lilly remains a point of contention.
November 8, 2024
·
4 min read
·
Greg Slabodkin
Manufacturing
Novo-Catalent Deal Represents ‘Defining Moment’ for CDMO Sector
Novo Holdings’ acquisition of Catalent has ignited concerns from industry stakeholders, who fear that the consolidation could limit competition, but there is also the possibility that the deal could represent an opportunity for smaller-scale CDMOs to find new partners.
November 13, 2024
·
4 min read
·
Ben Hargreaves
Deals
Amid Novo Buy, Catalent Offloads New Jersey Facility to Ardena
European CDMO Ardena will buy Catalent’s oral solids manufacturing facility in Somerset, N.J.
October 14, 2024
·
1 min read
·
Annalee Armstrong
Earnings
Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, 2024. The miss comes amid growing opposition to Novo Holdings’ proposed $16.5 billion acquisition of Catalent.
November 6, 2024
·
3 min read
·
Tristan Manalac
Editorial
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.
October 11, 2024
·
3 min read
·
Greg Slabodkin
Earnings
Roche Beats Q3 Sales Estimates as CEO Voices Opposition to Novo Holdings’ Catalent Buyout
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by strong performance of its multiple sclerosis therapy Ocrevus and eye injection Vabysmo.
October 23, 2024
·
3 min read
·
Tristan Manalac
Podcast
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona comes at a bad time for the company; Sen. Warren calls for scrutiny of Novo’s purchase of Catalent; and other news.
October 16, 2024
·
1 min read
·
Heather McKenzie
Press Releases
Catalent, Inc. Reports First Quarter Fiscal 2025 Results
November 5, 2024
·
19 min read
Deals
Catalent Stockholders Approve Transaction with Novo Holdings
Catalent, Inc. announced that, at its Special Meeting of Stockholders held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S will acquire all outstanding shares of Catalent for $63.50 per share in cash.
May 29, 2024
·
7 min read
1 of 43,217
Next
